Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon
- Resource Type
- Short Communication
- Authors
- Lew, Thomas E.; Bennett, Rory; Lin, Victor S.; Whitechurch, Ashley; Handunnetti, Sasanka M.; Marlton, Paula; Shen, Yandong; Mulligan, Stephen P.; Casan, Joshua; Blombery, Piers; Tam, Constantine S.; Roberts, Andrew W.; Seymour, John F.; Thompson, Philip A.; Anderson, Mary A.
- Source
- In Blood Advances 26 March 2024 8(6):1439-1443
- Subject
- Lymphoid Neoplasia
- Language
- ISSN
- 2473-9529